| Schedule of basic and diluted earnings per share, impact of two-class method |
The following table summarizes the impact of the two-class method: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended
June 30, | | Six months ended
June 30, | | (in millions, except per share data) | 2026 | | 2025 | | 2026 | | 2025 | | Basic EPS | | | | | | | | | Net earnings attributable to AbbVie Inc. | $ | 3,613 | | | $ | 938 | | | $ | 4,308 | | | $ | 2,224 | | | Earnings allocated to participating securities | 12 | | | 10 | | | 20 | | | 20 | | | Earnings available to common shareholders | $ | 3,601 | | | $ | 928 | | | $ | 4,288 | | | $ | 2,204 | | | Weighted-average basic shares outstanding | 1,769 | | | 1,768 | | | 1,769 | | | 1,768 | | | Basic earnings per share attributable to AbbVie Inc. | $ | 2.04 | | | $ | 0.52 | | | $ | 2.42 | | | $ | 1.25 | | | | | | | | | | | Diluted EPS | | | | | | | | | Net earnings attributable to AbbVie Inc. | $ | 3,613 | | | $ | 938 | | | $ | 4,308 | | | $ | 2,224 | | | Earnings allocated to participating securities | 12 | | | 10 | | | 20 | | | 20 | | | Earnings available to common shareholders | $ | 3,601 | | | $ | 928 | | | $ | 4,288 | | | $ | 2,204 | | | Weighted-average shares of common stock outstanding | 1,769 | | | 1,768 | | | 1,769 | | | 1,768 | | | Effect of dilutive securities | 2 | | | 3 | | | 4 | | | 4 | | | Weighted-average diluted shares outstanding | 1,771 | | | 1,771 | | | 1,773 | | | 1,772 | | | Diluted earnings per share attributable to AbbVie Inc. | $ | 2.03 | | | $ | 0.52 | | | $ | 2.42 | | | $ | 1.24 | |
|